Structure-dependent in vitro cytotoxicity of the isomeric complexes [Ru(L)2Cl2] (L=o-tolylazopyridine and 4-methyl-2-phenylazopyridine) in comparison to [Ru(azpy)2Cl2]
- 19 March 2004
- journal article
- research article
- Published by Springer Nature in JBIC Journal of Biological Inorganic Chemistry
- Vol. 9 (3) , 354-364
- https://doi.org/10.1007/s00775-004-0531-6
Abstract
The dichlorobis(2-phenylazopyridine)ruthenium(II) complexes, [Ru(azpy)2Cl2], are under renewed investigation due to their potential anticancer activity. The three most common isomers α-, β- and γ-[RuL2Cl2] with L=o-tolylazopyridine (tazpy) and 4-methyl-2-phenylazopyridine (mazpy) (α indicating the coordinating Cl, N(pyridine) and Nazo atoms in mutual cis, trans, cis positions, β indicating the coordinating Cl, N(pyridine) and Nazo atoms in mutual cis, cis, cis positions, and γ indicating the coordinating Cl, N(pyridine) and Nazo atoms in mutual trans, cis, cis positions) are synthesized and characterized by NMR spectroscopy. The molecular structures of γ-[Ru(tazpy)2Cl2] and α-[Ru(mazpy)2Cl2] are determined by X-ray diffraction analysis. The IC50 values of the geometrically isomeric [Ru(tazpy)2Cl2] and [Ru(mazpy)2Cl2] complexes compared with those of the parent [Ru(azpy)2Cl2] complexes are determined in a series of human tumour cell lines (MCF-7, EVSA-T, WIDR, IGROV, M19, A498 and H266). These data unambiguously show for all complexes the following trend: the α isomer shows a very high cytotoxicity, whereas the β isomer is a factor 10 less cytotoxic. The γ isomers of [Ru(tazpy)2Cl2] and [Ru(mazpy)2Cl2] display a very high cytotoxicity comparable to that of the γ isomer of the parent compound [Ru(azpy)2Cl2] and to that of the α isomer. These biological data are of the utmost importance for a better understanding of the structure–activity relationships for the isomeric [RuL2Cl2] complexes.Keywords
This publication has 12 references indexed in Scilit:
- New clues for platinum antitumor chemistry: Kinetically controlled metal binding to DNAProceedings of the National Academy of Sciences, 2003
- Ruthenium Complexes of 2-[(4-(Arylamino)phenyl)azo]pyridine Formed via Regioselective Phenyl Ring Amination of Coordinated 2-(Phenylazo)pyridine: Isolation of Products, X-ray Structure, and Redox and Optical PropertiesInorganic Chemistry, 2002
- Blood Concentration and Toxicity of the Antimetastasis Agent NAMI-A Following Repeated Intravenous Treatment in MiceBasic & Clinical Pharmacology & Toxicology, 2000
- Tuning the Rotational Behavior of Lopsided Heterocyclic Nitrogen Ligands (L) in Octahedral cis-[Ru(bpy)2(L)2](PF6)2 Complexes. A Variable-Temperature 1H NMR StudyInorganic Chemistry, 2000
- Synthesis, Characterization, and Crystal Structure of α-[Ru(azpy)2(NO3)2] (azpy = 2-(Phenylazo)pyridine) and the Products of Its Reactions with Guanine DerivativesInorganic Chemistry, 2000
- Strong Differences in the in Vitro Cytotoxicity of Three Isomeric Dichlorobis(2-phenylazopyridine)ruthenium(II) ComplexesInorganic Chemistry, 2000
- Current Status of Platinum-Based Antitumor DrugsChemical Reviews, 1999
- Non-Platinum Chemotherapeutic MetallopharmaceuticalsChemical Reviews, 1999
- Correlation between Cytotoxicity and DNA Binding of Polypyridyl Ruthenium ComplexesBiochemistry, 1995
- Comparison of the sulforhodamine B protein and tetrazolium (MTT) assays for in vitro chemosensitivity testingEuropean Journal of Cancer and Clinical Oncology, 1991